Suven Life Sciences Ltd
said that it has been granted a product patent from Australia and Singapore each for the treatment of disorders associated with Neurodegenerative diseases. These product patents are valid through 2036 respectively.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” says Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds, respectively, and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, Schizophrenia etc.
Suven Life Sciences Ltd is currently trading at Rs223.10 up by Rs4.05 or 1.85% from its previous closing of Rs219.05 on the BSE.
The scrip opened at Rs221 and has touched a high and low of Rs226.20 and Rs218.60 respectively.